Knight Therapeutics Inc.
TSX:GUD.TODrug Manufacturers - Specialty & Generic
+$0.07 today
- Market cap
- $1.14B
- Beta
- 0.07
- P/E (TTM)
- 164.6
- EPS (TTM)
- $0.06
Volume 0.04M
Average 0.10M
GUD.TO Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Knight Therapeutics Inc.TSX: GUD.TO
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings rises 2.6% from a year ago
Retained earnings stood at CA$160.84M at the end of Q1 FY2026, up 2.6% from a year earlier and up 8.0% from the prior quarter. Over 3 fiscal years it compounded at -2.7% a year.
Context
- Retained earnings amounted to 14.8% of total assets at the end of Q1 FY2026, down 0.8 pp from a year earlier.
- Retained earnings increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps rising in the next quarterly balance sheet after a +2.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
CAD · from the balance sheet
- Latest · FY2025
- 148.94M CAD
- Year-over-year change
- -3.8%
- 4-year CAGR
- -6.1%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 148.94M | -3.8% |
| FY2024 | 2024-12-31 | 154.79M | +2.6% |
| FY2023 | 2023-12-31 | 150.89M | -6.7% |
| FY2022 | 2022-12-31 | 161.76M | -15.6% |
| FY2021 | 2021-12-31 | 191.65M | — |
Retained Earnings vs competitors
How GUD.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +2.6% is the 3rd highest of 8, against a peer median of -1.9%.
- Retained earnings amounts to 14.8% of total assets for GUD.TO, versus a peer median of 113.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$160.84M CAD | +2.6% | -2.7% | 14.8% | |
| Mar 2026 | $106.35M USD | +32.5% | +25.5% | 69.3% | |
| Mar 2026 | CA$8.02M CAD | +1020.6% | — | 2.2% | |
| Mar 2026 | -CA$85.32M CAD | -11.0% | — | 61.6% | |
| Mar 2026 | -CA$589.68M CAD | -4.5% | — | 113.1% | |
| Mar 2026 | -$874.42M USD | -10.4% | — | 159.1% | |
| Mar 2026 | -CA$6.44B CAD | -1.2% | — | 1071.7% | |
| Mar 2026 | -CA$11.14B CAD | -1.9% | — | 995.6% | |
| Peer median (excluding GUD.TO) | — | -1.9% | +25.5% | 113.1% | |
Competitors are the stored peer set for GUD.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 85.96M | 71.68M | 58.76M | 80.11M | 76.45M |
| Short-term Investments | 77.03M | 119.54M | 95.66M | 92.73M | 18.83M |
| Net Receivables | 67.41M | 108.57M | 98.23M | 113.53M | 138.24M |
| Inventory | 72.4M | 92.49M | 91.83M | 102.7M | 135.87M |
| Other Current Assets | 2.35M | 19.29M | 15.75M | 14.02M | 18.95M |
| Total Current Assets | 307.32M | 395.62M | 365.12M | 396.81M | 394.84M |
| Property, Plant & Equipment (Net) | 29.94M | 22.63M | 17.86M | 20.02M | 21.93M |
| Goodwill | 75.4M | 82.27M | 79.84M | 86.48M | 89.98M |
| Intangible Assets | 350.3M | 338.78M | 289.96M | 283.61M | 379.51M |
| Long-term Investments | 178.95M | 158.02M | 120.02M | 103.43M | 124.24M |
| Tax Assets | 2.05M | 9.31M | 19.39M | 21.25M | 26.92M |
| Other Non-current Assets | 47.93M | 48.2M | 53.3M | 52.2M | 8.88M |
| Total Non-current Assets | 684.57M | 659.22M | 580.38M | 566.98M | 651.46M |
| Total Assets | 991.89M | 1.05B | 945.49M | 963.8M | 1.05B |
| Account Payables | 65.31M | 106.06M | 85.37M | 78.35M | 120.87M |
| Short-term Debt | 26.66M | 17.67M | 17.85M | 17.49M | 20.13M |
| Tax Payables | 7.07M | 2.27M | 1.18M | 213K | 0 |
| Deferred Revenue | 9.73M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.99M | 15.01M | 7.9M | 1.88M | 20.29M |
| Total Current Liabilities | 105.3M | 141.32M | 114.03M | 111.25M | 165.26M |
| Long-term Debt | 9.27M | 52.4M | 44.02M | 25.9M | 51.17M |
| Deferred Tax Liabilities | 12.37M | 4.37M | 2.82M | 3.84M | 2.99M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 19.52M | 25.85M | 32.26M | 24.27M | 52.99M |
| Total Non-current Liabilities | 44.57M | 87.66M | 84.59M | 57.44M | 113.77M |
| Total Liabilities | 149.87M | 228.98M | 198.62M | 168.69M | 279.03M |
| Common Stock | 628.85M | 599.06M | 540.05M | 534.27M | 530.14M |
| Retained Earnings | 191.65M | 161.76M | 150.89M | 154.79M | 148.94M |
| Accumulated OCI | (259K) | 41.38M | 29.95M | 80.22M | 55.74M |
| Other Stockholders Equity | 0 | 0 | 0 | 117K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 842.02M | 825.86M | 746.87M | 795.11M | 767.27M |
| Total Debt | 40.96M | 77.7M | 69.09M | 49.46M | 77.91M |
| Net Debt | (45.01M) | 6.02M | 10.33M | (30.65M) | 1.46M |
Knight Therapeutics Inc.
TSX:GUD.TO
Intrinsic Alpha fair value
Locked
Current Price
$11.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.